Staff Reports
The White House says nine more drug makers have signed on to its “most‑favored‑nation” (MFN) deals. That brings the total to 26 companies and, the administration claims, roughly 89% of the branded drug market. President Donald Trump and HHS Secretary Robert F. Kennedy Jr. pushed the news at an Oval Office event, and the White House cranked out a fact sheet full of bold savings claims.
What’s new in the MFN drug‑pricing push
The new companies named by the administration include Alcon, Astellas, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva, and UCB. The White House says the agreements open MFN pricing to state Medicaid programs and cover medicines for Parkinson’s, some cancers, macular degeneration, liver disease and more. The announcement also ties into the Medicare GLP‑1 Bridge, a CMS demonstration that lets some seniors get select GLP‑1 drugs for a $50 monthly copay — a headline every politician loves to show off.
Why conservatives should care about MFN and drug prices
Using purchase leverage and trade tools to lower drug prices is exactly the kind of pro‑consumer, pro‑market action conservatives should cheer. The administration says the Council of Economic Advisers models show more than $500–$600 billion in savings over time. If real, that kind of relief would be a big win for working families, seniors, and taxpayers. And yes, making onshoring commitments and tying tariff relief to deals is clever leverage — Business doesn’t hand you discounts for fun.
But don’t pop the champagne yet: key questions remain
The White House numbers look great on paper, but the math depends on big assumptions. The CEA’s savings projection assumes wide, lasting cuts and rules that haven’t been codified into law. Independent reviewers point out the voluntary deals we can see may be narrow or time‑limited. So here’s what we need: publish the actual deal texts or redacted summaries, show which exact drugs are covered and for how long, and say whether the prices being matched are list prices or net, rebated prices. In plain English: show the receipts. Otherwise Republicans will be handing Democrats a chance to scream “smoke and mirrors.”
Bottom line: a bold start, but demand proof
This administration deserves credit for using muscle to press lower drug prices. The MFN rollouts, TrumpRx tools, and the GLP‑1 Bridge are constructive steps that could help real people. Still, policy wins need follow‑through and transparency. Conservatives should cheer the intent, watch the roll‑out, and push hard for the deal details. If the White House’s numbers check out, it will be a major conservative policy victory — and if not, we’ll be glad we asked the tough questions from the start.
